Junshi Biosciences expands toripalimab’s treatment footprint in China with regulatory approval for a new urothelial carcinoma indication, strengthening immunotherapy options for patients with advanced bladder cancer.
Oncology Innovation | 25/05/2026 | By News Bureau
GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021
Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.
Oncology Innovation | 16/04/2026 | By News Bureau | 146
Oncodesign Services Expands Collaboration with GIP ARRONAX to Advance Targeted Radiotherapy Research
Oncodesign Services strengthens partnership with GIP ARRONAX to secure access to rare radionuclides like astatine-211, supporting preclinical development of next-generation targeted radiotherapy treatments for cancer and other diseases.
Oncology Innovation | 14/04/2026 | By News Bureau | 126
The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.
Oncology Innovation | 11/04/2026 | By News Bureau | 111
Eisai and Nuvation Bio Secure EMA Validation for Taletrectinib in Lung Cancer
EU regulator begins review of next-generation targeted therapy for advanced ROS1-positive non-small cell lung cancer.
Oncology Innovation | 30/03/2026 | By News Bureau | 159
PMDA Expands Use of Enhertu for Second-Line Gastric Cancer in Japan
Regulatory update allows Enhertu to be used earlier in treatment for HER2-positive advanced gastric cancer, backed by phase III data showing improved survival outcomes.
Oncology Innovation | 25/03/2026 | By News Bureau | 246
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy